Optimal Timing of Hepatitis B Vaccination After Transplants
- Conditions
- Transplant-Related DisorderHepatitis B Virus InfectionVaccine Reaction
- Interventions
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Target Recruit Count
- 1500
- Registration Number
- NCT06888479
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
- Conditions
- HIV Infected IndividualsHIV
- Interventions
- Biological: HIV-CAR-T
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 3
- Registration Number
- NCT06880380
Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model
- Conditions
- Acute Graft-versus-Host Disease
- Interventions
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 174
- Registration Number
- NCT06880419
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: anti-BCMA-CAR-T
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 40
- Registration Number
- NCT06880393
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: CLL1 and CD38 Dual-Target CAR-T Cell Injection
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-03-17
- Target Recruit Count
- 37
- Registration Number
- NCT06880354
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, TianJin, China
Newly-diagnosed Pediatric T-cell ALL Protocol
- Conditions
- Acute Lymphoblastic LeukemiaChildhood Leukemia, Acute LymphoblasticT Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-14
- Target Recruit Count
- 610
- Registration Number
- NCT06855810
- Locations
- 🇨🇳
Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
🇨🇳Anhui Provincial Children's Hospital, Hefei, Anhui, China
🇨🇳Chongqing Medical University Affiliated Children's Hospital, Chongqing, Chongqing, China
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 80
- Registration Number
- NCT06838949
- Locations
- 🇨🇳
Chinese academy of medical science and blood disease hospital, Tianjin, China
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
- Conditions
- Immune Thrombocytopenia (ITP)Treatment
- Interventions
- Drug: CM336 Injection
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 20
- Registration Number
- NCT06799611
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Target Recruit Count
- 80
- Registration Number
- NCT06793449
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- Conditions
- Extramedullary Multiple Myeloma
- Interventions
- Biological: anti-BCMA/GPRC5D bispecific CAR-TDrug: Apornemin
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 20
- Registration Number
- NCT06793475
- Locations
- 🇨🇳
Beijing Gobroad Boren Hospital, Beijing, China
🇨🇳Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China